CD180 (RP105) Mouse anti-Human, Clone: MHR73-11, eBioscience™

Mouse Monoclonal Antibody

Overview
Brand: Affymetrix eBioscience

Manufacturer Part Number: 14-1809-80

25UG:ANTI-HUMAN CD180 (RP105) PURIFIED 25 UG

UNSPSC: 12352200

Code: Z2

Additional Details:
Additional Details: Weight: 0.01000kg



Disclaimers: For Research Use Only.

Product Code. 15217277

Quantity Price
1 £ 82.0 / 25µg
Estimated Shipment date
from Supplier 12-12-2016
Add to basket


Description and Specification

Specification

Antigen CD180 (RP105)
Applications Flow Cytometry
Applications Functional Assay
Applications Immunohistochemistry
Applications Immunoprecipitation
Clone MHR73-11
Concentration 0.5mg/mL
Conjugate Unlabeled
Format Purified
Formulation aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer
Gene Alias RP-105, Toll-like Receptor, TLR Family
Host Species Mouse
Isotype IgG1
Quantity 25μg
Regulatory Status RUO
Species Reactivity Human
Storage Requirements Store at 2-8°C.
Primary or Secondary Primary
Monoclonal or Polyclonal Monoclonal

The MHR73-11 monoclonal antibody reacts with human CD180 (RP105). This 105kDa type I transmembrane molecule is a member of the TLR family of proteins characterized by an extracellular domain with leucine-rich repeats and a cytoplasmic domain with homology to the type I IL-1 receptor. RP105 physically associates with another molecule called MD-1 and is expressed on B, monocytes/macrophages, and dendritic cells. Histological studies show that RP105 is expressed mainly on mature B cells in mantle zones, while germinal center cells are either dull or negative. The RP105/MD-1 complex in concert with TLR4 mediates B cell recognition and signaling of LPS. MHR73-11 activates B cells, leading to increases in cell size, expression of the costimulatory molecule CD80, and DNA synthesis. Moreover, ligation of RP105 protects B cells from irradiation- or dexamethasone-induced apoptosis. Thus, RP105 is a signal transduction molecule and plays a role in regulation of B cell growth and death. A significant proportion of circulating B cells in SLE patients is RP105 negative. Loss of RP105 is associated with B cell activation and increased disease activity in SLE patients.